- Q2 2020 Revenue of $10.8 million; EBITDA loss of $0.7 million
- July 2020 & August revenue of $15.1 million1
All figures are reported in United States dollars ($) unless otherwise indicated
LAS VEGAS, NV / ACCESSWIRE / August 31, 2020 / Planet 13 Holdings Inc. (CSE:PLTH) (OTCQB:PLNHF) ("Planet 13" or the "Company"), a leading vertically-integrated Nevada cannabis company, today announced its financial results for the three-month and six-month period ended June 30, 2020. Planet 13's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").
Larry Scheffler, Co-CEO of Planet 13 commented, "Q2 was a challenging environment for all Nevada businesses. I'm pleased with the way the team worked under these conditions to add new customers and preserve capital. As the State has reopened, we've seen an incredible pickup in our business, with July and August being our highest months of sales to date. The SuperStore is seeing increased customer conversion and higher tickets, while our delivery team is servicing local customers and providing approximately 15% of our sales compared to less than 1% pre-COVID."
Bob Groesbeck, Co-CEO added, "Our brands are performing well at the SuperStore, up from 14% in Q4 2019 to 28.5% of sales in Q2 2020. This number will continue to increase now that we have expanded cultivation to supply our popular Medizin line. We are also seeing initial success in the wholesale market, which we began supplying in June. Our products are now available in 33 dispensaries in Nevada, and we have multiple SKUs in the top 10 of their respective categories; edibles, concentrates, and beverages2. Planet 13 has resumed its growth trajectory. In July and August we've generated our highest revenue ever, over $7 million per month. We are set to build on this momentum reopening our Medizin dispensary shortly and Santa Ana in 2021. I'm incredibly excited about what the future holds for Planet 13."
1August revenue is for the first 30 days of the month
Financial Highlights - Q2 - 2020
Operating Results
All comparisons below are to the quarter ended June 30, 2019, unless otherwise noted
- Revenues were $10.8 million as compared to $16.5 million, a decrease of 34.9%
- Gross profit before biological adjustments was $4.7 million or 43.8% as compared to $9.7 million or 58.7%, a decrease of 51.5%
- Operating expenses, excluding non-cash compensation expense, were $5.8 million as compared to $7.1 million, a decrease of 18.5%
- Net loss before taxes of $3.3 million as compared to a net income of $1.1 million
- Net loss of $4.0 million as compared to a net loss of $0.9 million
- Adjusted EBITDA loss of $0.7 million as compared to Adjusted EBITDA of $2.7 million
Balance Sheet
All comparisons below are to December 31, 2019, unless otherwise noted
- Cash of $22.7 million as compared to $12.8 million
- Total assets of $81.9 million as compared to $62.9 million
- Total liabilities of $30.9 million as compared to $21.6 million
Q2 Highlights and Recent Developments
For a more comprehensive overview of these highlights and recent developments, please refer to Planet 13's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three Months and Six Months Ended June 30, 2020 (the "MD&A").
- On April 13, 2020, Planet 13 announced termination of the Santa Ana acquisition.
- On April 17, 2020, Planet 13 announced the renegotiation of the Santa Ana acquisition.
- On May 21, 2020, Planet 13 announced the acquisition of a dispensary license and the close of the Santa Ana acquisition.
- On June 15, 2020, Planet 13 announced a CDN$10 million bought deal public offering.
- On July 3, 2020, Planet 13 announced closing of a CDN$11.5 million bought deal public offering.
- On July 17, 2020, Planet 13 announced an acquisition of 45,000 square feet of indoor cultivation.
- On August 10, 2020, Planet 13 was awarded a Nevada dispensary license.
- On August 20, 2020, Planet 13 announced a CDN$15 million bought deal public offering.
- On August 21, 2020, Planet 13 announced an upsize to bought deal public offering to CDN$20 million.
Results of Operations (Summary)
The following tables set forth consolidated statements of financial information for the three-month and six-month periods ending June 30, 2020 and June 30, 2019. For further information regarding the Company's financial results for these periods, please refer to the Company's interim financial statements for the period ended June 30, 2020 together with the MD&A, available on Planet 13's issuer profile on SEDAR at www.sedar.com and the Company's website https://www.planet13holdings.com.
Adjusted EBITDA
| NV Cannabis Ops | Consolidated | Consolidated | ||||||||||||||
| Three Months | Three Months | Three Months | ||||||||||||||
| Ended | Ended | Ended | Percentage | |||||||||||||
| Jun-30-2020 | Jun-30-2020 | Jun-30-2019 | Change | |||||||||||||
| EBITDA | ||||||||||||||||
| Profit (loss) before taxes | (2,425,120 | ) | (3,286,823 | ) | 1,064,222 | (408.8 | %) | |||||||||
| Add back: | ||||||||||||||||
| Biological asset adjustments | (44,356 | ) | (44,356 | ) | 89,519 | (149.5 | %) | |||||||||
| Non-cash share based payments | - | 626,017 | 539,262 | 16.1 | % | |||||||||||
| Depreciation and amortization | 1,040,065 | 1,040,065 | 668,041 | 55.7 | % | |||||||||||
| Depreciation included in COGS | 406,322 | 406,322 | 157,297 | 158.3 | % | |||||||||||
| Interest and non-operating expense (income) | 568,154 | 568,154 | 213,115 | 166.6 | % | |||||||||||
| EBITDA | (454,935 | ) | (690,621 | ) | 2,731,456 | (125.3 | %) | |||||||||
| Margin | (4.2 | %) | (6.4 | %) | 16.5 | % | ||||||||||
| Expressed in USD$ | Three Months | Three Months | ||||||||||
| Ended | Ended | Percentage | ||||||||||
| Jun-30-2020 | Jun-30-2019 | Change | ||||||||||
| Revenue | ||||||||||||
| Revenues, net of discounts | 10,760,996 | 16,521,717 | (34.9 | %) | ||||||||
| Cost of Goods Sold | (6,051,963 | ) | (6,826,598 | ) | (11.3 | %) | ||||||
| Gross Profit, Before Biological Asset Adjustment | 4,709,033 | 9,695,119 | (51.4 | %) | ||||||||
| Gross Profit Margin % | 43.8 | % | 58.7 | % | ||||||||
| Realized fair value amounts included in COGS | (327,997 | ) | 102,919 | (418.7 | %) | |||||||
| Unrealized fair value gain on growth of biological assets | 372,353 | (192,438 | ) | (293.5 | %) | |||||||
| Gross profit | 4,753,389 | 9,605,600 | (50.5 | %) | ||||||||
| Gross Profit Margin % | 44.2 | % | 58.1 | % | ||||||||
| Expenses | ||||||||||||
| General and Administrative | 5,559,623 | 5,476,208 | 1.5 | % | ||||||||
| Sales and Marketing | 246,353 | 1,644,752 | (85.0 | %) | ||||||||
| Depreciation and Amortization | 1,040,065 | 668,041 | 55.7 | % | ||||||||
| Share based payments | 626,017 | 539,262 | 16.1 | % | ||||||||
| Total Expenses | 7,472,058 | 8,328,263 | (10.3 | %) | ||||||||
| Income (Loss) From Operations | (2,718,669) | 1,277,337 | (312.8 | %) | ||||||||
| Other (Income) Expense: | ||||||||||||
| Interest Expense, net | 572,257 | 372,456 | 53.6 | % | ||||||||
| Realized Foreign Exchange gain (loss) | - | 2,337 | (100.0 | %) | ||||||||
| Other expense (income) | (4,103 | ) | (161,678 | ) | (97.5 | %) | ||||||
| Total Other Expense (Income) | 568,154 | 213,115 | 166.6 | % | ||||||||
| Income (loss) for the period before tax | (3,286,823) | 1,064,222 | (408.8 | %) | ||||||||
| Provision for income tax (current and deferred) | 701,272 | 1,999,690 | (64.9 | %) | ||||||||
| (Loss) for the period | (3,988,095) | (935,468) | 326.3 | % | ||||||||
| Other Comprehensive Income (Loss) | ||||||||||||
| Items that may be reclassified subsequently to profit/loss | ||||||||||||
| Foreign exchange translation adjustment | (83,699 | ) | (82,316 | ) | ||||||||
| Net Comprehensive (Loss) for the period | (4,071,794) | (1,017,784) | ||||||||||
| (Loss) per share for the period | ||||||||||||
| Basic and fully diluted loss per share | $ | (0.03) | $ | (0.01) | ||||||||
| Weighted Average Number of Shares Outstanding | ||||||||||||
| Basic and fully diluted | 143,947,783 | 133,533,681 | ||||||||||
Outstanding Shares
As of August 30, 2020, the Company had 104,104,733 common shares and 59,173,872 class A convertible, restricted voting shares issued and outstanding for a total of 163,278,605 shares outstanding. There were 433,840 options issued and outstanding of which all have fully vested. There were 5,430,332 warrants outstanding and 1,764,250 RSU's outstanding of which nil RSUs had fully vested as of August 30, 2020.
Conference Call
Planet 13 will host a conference call on Monday, August 31, 2020 at 5:00 p.m. EST to discuss its second quarter financial results and provide investors with key business highlights. The call will be chaired by Bob Groesbeck, Co-CEO, Larry Scheffler, Co-CEO, and Dennis Logan, CFO.
CONFERENCE CALL DETAILS
Date: August 31, 2020 | Time: 5:00 p.m. EST
Participant Dial-in: Toll Free 877-407-8035 or International 201-689-8035
Replay Dial-in: Toll Free 877-481-4010 or International 919-882-2331
(Available for 2 weeks)
Reference Number: 36624
Listen to webcast: https://bit.ly/3h6DVfA
Financial Measures
There are measures included in this news release that do not have a standardized meaning under generally accepted accounting principles (GAAP) and therefore may not be comparable to similarly titled measures and metrics presented by other publicly traded companies. The Company includes these measures because it believes certain investors use these measures and metrics as a means of assessing financial performance. EBITDA (earnings before interest, taxes, depreciation and amortization) is calculated as net earnings before finance costs (net of finance income), income tax expense, and depreciation and amortization of intangibles and is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.
For further inquiries, please contact:
LodeRock Advisors Inc., Planet 13 Investor Relations
mark.kuindersma@loderockadvisors.com
(416) 519-2156 ext. 2230
Bob Groesbeck and Larry Scheffler
Co-Chief Executive Officers
ir@planet13lasvegas.com
About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas - the entertainment capital of the world. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company's business, including COVID-19, are contained under the heading "Risk Factors" and elsewhere in the Company's annual information form dated April 13, 2020 filed on its issuer profile on SEDAR at www.sedar.com.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
| Expressed in United States Dollars | As at | As at | ||||||
| June 30, | December 31, | |||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | 22,724,824 | $ | 12,814,712 | ||||
| HST receivable | 110,192 | 16,544 | ||||||
| Inventories (Note 5) | 5,775,633 | 5,474,004 | ||||||
| Biological assets (Note 6) | 699,850 | 514,526 | ||||||
| Prepaid expenses and other current assets (Note 10) | 1,723,608 | 3,694,272 | ||||||
| Total Current Assets | 31,034,107 | 22,514,058 | ||||||
| Property and equipment (Note 7) | 30,053,518 | 30,211,154 | ||||||
| Licenses (Note 8) | 5,607,238 | - | ||||||
| Right of use assets (Note 9) | 13,555,904 | 9,478,733 | ||||||
| Deferred tax asset | 28,779 | - | ||||||
| Long-term deposits and other assets | 1,189,318 | 694,601 | ||||||
| 50,434,757 | 40,384,488 | |||||||
| Total Assets | $ | 81,468,864 | $ | 62,898,546 | ||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 2,516,299 | $ | 864,260 | ||||
| Accrued expenses | 2,210,801 | 1,910,046 | ||||||
| Income taxes payable | 9,838,881 | 7,015,606 | ||||||
| Notes payable - current portion (Note 11) | 884,000 | 884,000 | ||||||
| Total Current Liabilities | 15,449,981 | 10,673,912 | ||||||
| Long -term lease liabilities (Note 12) | 15,060,344 | 10,522,377 | ||||||
| Other long-term liabilities | 28,000 | 28,000 | ||||||
| Deferred tax liability | - | 379,665 | ||||||
| 15,088,344 | 10,930,042 | |||||||
| Total Liabilities | 30,538,325 | 21,603,954 | ||||||
| Shareholders' Equity | ||||||||
| Share capital (Note 13) | 69,411,212 | 51,986,849 | ||||||
| Restricted share units (Note 13) | 3,397,735 | 4,119,485 | ||||||
| Warrants (Note 13) | 4,367,973 | 5,961,091 | ||||||
| Option reserve (Note 13) | 375,678 | 399,439 | ||||||
| Accumulated other comprehensive loss | (660,337 | ) | (607,707 | ) | ||||
| Deficit | (25,961,722 | ) | (20,564,565 | ) | ||||
| Total Shareholders' Equity | 50,930,539 | 41,294,592 | ||||||
| Total Liabilities and Shareholders' Equity | $ | 81,468,864 | $ | 62,898,546 | ||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND
COMPREHENSIVE INCOME (LOSS)
| Expressed in United States Dollars | Three months | Three months | ||||||
| Ended | Ended | |||||||
| June 30, | June 30, | |||||||
| 2020 | 2019 | |||||||
| Revenue | ||||||||
| Revenues, net of discounts | $ | 10,760,996 | $ | 16,521,717 | ||||
| Cost of Goods Sold | (6,051,963 | ) | (6,826,598 | ) | ||||
| Gross Profit before fair value asset adjustment | 4,709,033 | 9,695,119 | ||||||
| Realized fair value amounts included in inventory sold | (327,997 | ) | 102,919 | |||||
| Unrealized fair value gain on growth of biological assets | 372,353 | (192,438 | ) | |||||
| Gross Profit | 4,753,389 | 9,605,600 | ||||||
| Expenses | ||||||||
| General and Administrative (Note 14) | 5,559,623 | 5,476,208 | ||||||
| Sales and Marketing | 246,353 | 1,644,752 | ||||||
| Depreciation and Amortization (Note 7 & 9) | 1,040,065 | 668,041 | ||||||
| Share-Based Compensation Expense (Note 13) | 626,017 | 539,262 | ||||||
| Total Expenses | 7,472,058 | 8,328,263 | ||||||
| Income (Loss) From Operations | (2,718,669) | 1,277,337 | ||||||
| Other Expense: | ||||||||
| Interest expense, net | 572,257 | 372,456 | ||||||
| Realized foreign exchange loss | - | 2,337 | ||||||
| Other income | (4,103 | ) | (161,678 | ) | ||||
| Total Other Expense | 568,154 | 213,115 | ||||||
| Income (Loss) before income taxes | (3,286,823) | 1,064,222 | ||||||
| Provision for tax - current | 866,710 | 1,999,690 | ||||||
| Provision for tax - deferred | (165,438 | ) | - | |||||
| Loss for the Period | $ | (3,988,095) | $ | (935,468) | ||||
| Other Comprehensive Income | ||||||||
| Foreign exchange translation gain (loss) | (83,699 | ) | (82,316 | ) | ||||
| Net Comprehensive Loss for the Period | $ | (4,071,794) | $ | (1,017,784) | ||||
| Loss per share for the Period | ||||||||
| Basic and diluted loss per share | $ | (0.03) | $ | (0.01) | ||||
| Weighted Average Number of Common Shares Outstanding | ||||||||
| Basic and Diluted | 143,947,783 | 133,533,681 | ||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Expressed in United States Dollars | Six Months | Six Months | ||||||
| Ended | Ended | |||||||
| June 30, | June 30, | |||||||
| 2020 | 2019 | |||||||
| Operating activities | ||||||||
| Net loss for the period | $ | (5,397,157 | ) | $ | (2,358,812 | ) | ||
| Add (deduct) non-cash items: | ||||||||
| Share based payments (Note 13) | 1,436,840 | 1,224,131 | ||||||
| Depreciation and amortization (Note 7 & 9) | 2,846,655 | 1,580,761 | ||||||
| Deferred tax liability | (379,665 | ) | (284,491 | ) | ||||
| Deferred tax asset | (28,779 | ) | - | |||||
| Realized fair value amounts included in inventory sold | - | (102,919 | ) | |||||
| Unrealized fair value gain on growth of biological assets | - | 192,438 | ||||||
| Non-cash interest expense on ROU Liabilities | 1,075,663 | - | ||||||
| Net change in non-cash working capital | ||||||||
| HST receivable | (93,648 | ) | (78,597 | ) | ||||
| Inventories (Note 5) | (301,629 | ) | (11,150 | ) | ||||
| Biological assets (Note 6) | (185,324 | ) | (89,519 | ) | ||||
| Prepaid expenses and other assets (Note 10) | 1,970,664 | (2,780,552 | ) | |||||
| Long term deposits and other assets | (494,717 | ) | (70,000 | ) | ||||
| Accounts payable | 1,652,038 | 1,510,420 | ||||||
| Accrued expenses | 300,756 | 256,246 | ||||||
| Income tax payable | 2,823,275 | 3,849,799 | ||||||
| Cash flow provided by operating activities | 5,224,972 | 2,837,755 | ||||||
| Investing activities | ||||||||
| Purchase of property, plant and equipment (Note 7) | (2,352,575 | ) | (5,946,852 | ) | ||||
| Purchase of license (Note 8) | (1,153,407 | ) | - | |||||
| Cash flow used in investing activities | (3,505,982) | (5,946,852) | ||||||
| Financing activities | ||||||||
| Issuance of shares on warrant and option exercises (Note 13) | 9,195,063 | 3,744,711 | ||||||
| Payment on lease liabilities | (951,311 | ) | (15,934 | ) | ||||
| Cash flow provided by financing activities | 8,243,752 | 3,728,777 | ||||||
| Net increase in cash | 9,962,742 | 619,680 | ||||||
| Cash at beginning of the period | 12,814,712 | 19,364,086 | ||||||
| Effect of foreign exchange on cash | (52,630 | ) | (26,436 | ) | ||||
| Cash at end of the period | $ | 22,724,824 | $ | 19,957,330 | ||||
SOURCE: Planet 13 Holdings Inc.
View source version on accesswire.com:
https://www.accesswire.com/604087/Planet-13-Announces-Second-Quarter-2020-Financial-Results
